High FASN Expression Linked to Kidney Cancer Drug Resistance
A phase 3 trial analysis suggests lipogenic metabolism may help explain why some advanced renal cell carcinoma patients stop responding to sunitinib.
Updated on Nov. 20, 2026 in Cancer

Researchers analyzing 743 patients in the phase 3 JAVELIN Renal 101 trial found that high fatty acid synthase (FASN) expression was associated with resistance to tyrosine kinase inhibitors and shorter progression-free survival in advanced renal cell carcinoma treated with sunitinib. The study was presented at the IKCS: North America 2026 meeting in Dallas, Texas.
Why it matters
The findings point to lipogenic metabolism as a possible mechanism of treatment resistance, which could help identify patients less likely to benefit from sunitinib. The researchers stated the results support further investigation of this pathway.
The analysis compared 377 sunitinib-treated and 366 avelumab-plus-axitinib-treated patients, with a hazard ratio of 1.19 per standard deviation of FASN expression in the sunitinib arm (P=.0015). The mechanistic link between FASN and resistance remains unconfirmed by the study.
The players
JAVELIN Renal 101 trial
A phase 3 clinical trial evaluating avelumab plus axitinib against sunitinib in advanced renal cell carcinoma, supported by Pfizer.
Pfizer
A multinational pharmaceutical company that supported the JAVELIN trial.
The details
Patients were grouped into low, intermediate and high FASN expression tertiles, and Kaplan-Meier and Cox regression analyses identified associated genes. FASN expression correlated positively with proliferative-stromal and proliferative-anabolic gene signatures and negatively with an angiogenic signature. The combination's relative benefit over sunitinib grew with FASN expression, with hazard ratios of 0.81, 0.72 and 0.49 across the low, intermediate and high groups.
Timeline
November 19-21, 2026: Results presented at IKCS: North America 2026 in Dallas, Texas.
Health Landscape
The study extends the original JAVELIN Renal 101 results by examining FASN expression within the same patient population, moving beyond the trial's headline comparison of combination therapy against sunitinib. It adds to a growing effort to identify biomarkers that predict which advanced kidney cancer patients benefit from newer combination regimens.
For patients with advanced kidney cancer, this research is preliminary and does not change current treatment selection. Any future use of FASN as a marker would require validation in clinical settings before it could inform decisions about sunitinib or combination therapy.
The takeaway
Biomarkers such as FASN expression may eventually help match advanced kidney cancer patients to the most effective therapy, though this link still needs confirmation in further studies.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Cancer Therapy Advisor.



